PARP Inhibitor Combinations in Prostate Cancer: Expanding Treatment Options to Broader Patient Populations

Download All
Learn how experts incorporate the newest evidence from ASCO 2021 on PARP inhibitor–based combinations into optimal management of prostate cancer with an on-demand webcast from a live webinar plus an expert commentary, podcast, and downloadable slidesets with ExpressPoints slides.
Charles J. Ryan, MD
Program Director
person default
Wassim Abida, MD, PhD
Joaquin Mateo, MD, PhD
Charles J. Ryan, MD

Downloadable Slidesets

Download this short summary slideset from a live Webinar to review the rationale for PARP inhibitor combination therapy in prostate cancer and current clinical data in metastatic castration-resistant prostate cancer

person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD Charles J. Ryan, MD Released: June 23, 2021

Download these slides from a live Webinar for the latest evidence on PARP inhibitor monotherapy and factors that impact response to PARP inhibition in metastatic castration-resistant prostate cancer.

person default Wassim Abida, MD, PhD Released: June 15, 2021

Download these slides from a live Webinar to learn about the rationale underlying PARP inhibitor combination therapeutic strategies in metastatic castration-resistant prostate cancer.

Joaquin Mateo, MD, PhD Released: June 15, 2021

Download these slides from a live Webinar to review the most recent clinical data on PARP inhibitors in combination with other agents in metastatic castration-resistant prostate cancer.

Charles J. Ryan, MD
Program Director
Released: June 14, 2021

On-Demand Webcast

Learn about the underlying rationale for PARP combination approaches in prostate cancer and discover the many ongoing clinical trials of PARP inhibitors combined with AR-directed therapy, immunotherapy, or other targeted agents.

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 7, 2021 Expired: July 6, 2022

ClinicalThought

In this commentary, gain insights on the rationale for PARP inhibitor combinations in prostate cancer and the latest corresponding evidence available.

Charles J. Ryan, MD Released: July 2, 2021

Podcast

In this podcast episode, listen to Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, as they answer questions on the use of PARP inhibitors and PARP inhibitor combinations for patients with prostate cancer.

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Released: June 30, 2021

Download this short summary of key takeaways from a podcast on combination approaches to expand the benefit of PARP inhibitors in prostate cancer.

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Released: June 30, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue